Defining co-related parameters between 'cymetabolic' flare and 'cyclinical', 'cybiochemical', and 'cyosteoblastic' flare and establishing guidelines for assessing response to treatment in cancer

被引：20

作者：

Basu, Sandip ^{[1
]}

Alavi, Abass ^{[1
]}

机构：

[1] Hosp Univ Penn, Div Nucl Med, Philadelphia, PA 19104 USA

来源：

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2007年 / 34卷 / 04期

关键词：

D O I：

10.1007/s00259-006-0264-6

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 [临床医学]; 100207 [影像医学与核医学]; 1009 [特种医学];

摘要：

引用

页码：441 / 443

页数：3

共 19 条

[1]

Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-releasing hormone analogue in prostate cancer and benign prostatic hyperplasia [J].

Agarwal, DK ;

Costello, AJ ;

Peters, J ;

Sikaris, K ;

Crowe, H .

BJU INTERNATIONAL, 2000, 85 (06) :690-695

[2]

Is it time to incorporate quantitative functional imaging data, FDG PET in particular, into the response evaluation criteria in solid tumours? [J].

Basu, Sandip ;

Nair, Narendra .

NUCLEAR MEDICINE COMMUNICATIONS, 2006, 27 (05) :413-416

[3]

FDG-PET in monitoring therapy of breast cancer [J].

Biersack, HJ ;

Bender, H ;

Palmedo, H .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 (Suppl 1) :S112-S117

[4]

Is the flare phenomenon clinically significant? [J].

Bubley, GJ .

UROLOGY, 2001, 58 (2A) :5-9

[5]

COLEMAN RE, 1988, J NUCL MED, V29, P1354

[6]

Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy [J].

Dehdashti, F ;

Flanagan, FL ;

Mortimer, JE ;

Katzenellenbogen, JA ;

Welch, MJ ;

Siegel, BA .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (01) :51-56

[7]

KAHAN A, 1984, LANCET, V1, P971

[8]

Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer [J].

Koizumi, M ;

Matsumoto, S ;

Takahashi, S ;

Yamashita, T ;

Ogata, E .

CLINICAL NUCLEAR MEDICINE, 1999, 24 (01) :15-20

[9]

Kostakoglu L, 2004, J NUCL MED, V45, P56

[10]

PREVENTION OF THE TRANSIENT ADVERSE-EFFECTS OF A GONADOTROPIN-RELEASING HORMONE ANALOG (BUSERELIN) IN METASTATIC PROSTATIC-CARCINOMA BY ADMINISTRATION OF AN ANTIANDROGEN (NILUTAMIDE) [J].

KUHN, JM ;

BILLEBAUD, T ;

NAVRATIL, H ;

MOULONGUET, A ;

FIET, J ;

GRISE, P ;

LOUIS, JF ;

COSTA, P ;

HUSSON, JM ;

DAHAN, R ;

BERTAGNA, C ;

EDELSTEIN, R .

NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (07) :413-418

← 1 2 →